Yakira Capital Management, Inc. Inhibrx, Inc. Transaction History

Yakira Capital Management, Inc.

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2024 May 14, 2024	BUY	$32.76 - $39.56 $1.76 Million - $2.13 Million	53,762 New	53,762 $1.88 Million

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Yakira Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Yakira Capital Management, Inc. with notifications on news.